Aprea Q2 Loss Widens to $0.07/Share as R&D Costs Climb; Cash Runway Extended to Q1 2028
APRE sits 20% above its 52-week low of $0.548 on light trading volume (0.2× avg).
Summary
Aprea's Q2 net loss widened to $3.6M, or $0.07 per share, driven by higher R&D spending as it expands the Phase 1 trial for its WEE1 inhibitor APR-1051. Cash rose to $41.2M after a $30M private placement, extending runway into Q1 2028. The company plans to report next clinical data in Q4 2026 and complete dose escalation by Q2 2027. This follows the July 30 news of trial site expansion and the Nasdaq extension to January 2027 to regain compliance. The widening loss and increased burn rate are material for a micro-cap biotech with a $0.66 stock price, though the cash position provides a multi-year cushion.
At the time of this announcement, APRE was trading at $0.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.2M. The 52-week trading range was $0.55 to $1.79. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.